We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by WHO critical-priority resistant Gram-negative bacteria.
Infex focuses on pandemic preparedness with Covid patent
Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains.
Latest News
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which…
Infex focuses on pandemic preparedness with Covid patent
Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all…
Introducing Infex Therapeutics
The organisation leading UK efforts to tackle the health crisis around our dwindling…
Major boost in global fight against antimicrobial resistance as AMR Centre receives share of Strength in Places Fund award
The AMR Centre has combined forces to attract much needed investment to combat the global…
The AMR Centre signs agreement to co-develop treatment for gonorrhoea
The AMR Centre (AMRC) has today announced a multi-year co-development agreement with…
More People in the United States Dying from Antibiotic-Resistant Infections than Previously Estimated
Significant progress since 2013 could be lost without more action
AMR Centre candidate targets superbugs with problem metallo-β-lactamase enzymes
The AMR Centre has nominated a preclinical candidate in its program that tackles drug…